MedPath

Characterization of AmnioExcel Plus in Two Treatment Paradigms

Not Applicable
Completed
Conditions
Diabetic Foot Ulcer
Interventions
Device: Amnio Excel + weekly
Device: Amnio Excel + max every 2 weeks
Registration Number
NCT04233580
Lead Sponsor
University of Texas Southwestern Medical Center
Brief Summary

The Investigators plan to evaluate healing in two cohorts of patients with diabetic foot wounds (n=20) that receive optimal treatment including serial wound debridement and off-loading with a boot or postop shoe and AmnioEXCEL+. In one cohort, AmnioEXCEL+ will be applied weekly at study visits and in the second cohort, AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC). In addition, the Investigators will collect data on other potential confounding factors that could affect healing such as antibiotic, anti-fungal and anti-infective medications, tobacco, comorbidities, diabetes control, infection, perfusion, and activity. Wound healing, including wound size and adverse events will be evaluated.

Detailed Description

Study Procedures:

Collection of Demographic data, medical/social history Collection of medications1 Ankle Brachial Index2 Wound debridement3 (standard of care procedure) Imaging with eKare4 Hyperspectral Imaging Application of study product

1. Only collect antibiotics, anti-fungal and anti-infective medications.

2. ABI (with toe pressure) can be done at screening or baseline.

3. Once wound is healed, wound debridement will not be done at weekly visits.

4. Once wound is healed, eKare will not be done at weekly visits.

5. EOS will occur on the date the subject is healed. \*Screening and Visit 1 may be done on the same day.

Screening and Enrollment\*:

* Review and sign the Informed Consent and HIPAA Authorization

* Review the inclusion and exclusion criteria

If the subject qualifies for the study, they will participate in the following procedures (weekly visits, +/-4 days):

Visit 1\*:

* Demographics (such as age, gender, race or ethnicity)

* Past Medical History, Social History, Medications documented.

* Labs documented as SOC within 6mo of initial visit

* ABI with toe pressures2

* Wound debridement

* eKare wound measurement

* Hyperspectral Imaging

* Randomization

* Application of AmnioEXCEL+

* Source documentation

* Stipend disbursement

Visits 2 through 6:

* Wound debridement3

* eKare wound measurement4

* Hyperspectral imaging

* Application of AmnioEXCEL+ per cohort assignment

* Source documentation

* Stipend disbursement

Visit 7:

* Medications documented

* Wound debridement3

* eKare wound measurement4

* Hyperspectral imaging

* Application of AmnioEXCEL+ per cohort assignment

* Source documentation

* Stipend disbursement

Visits 8-11:

* Wound debridement3

* eKare wound measurement4

* Hyperspectral Imaging

* Application of AmnioEXCEL+ per cohort assignment

* Source documentation

* Stipend disbursement

Visit 12:

* Wound debridement3

* eKare wound measurement4

* Source documentation

* Stipend disbursement

End of Study (EOS) Visit 5:

* Medications documented

* Wound debridement3

* eKare wound measurement4

* Source documentation

* Subject exit from study

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Weekly AmnioEXCEL+ groupAmnio Excel + weeklyAmnioEXCEL+ will be applied weekly at study visits
PRN AmnioEXCEL+ groupAmnio Excel + max every 2 weeksAmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC)
Primary Outcome Measures
NameTimeMethod
Number of Participants Who Healed12 weeks

Number of participants whose wounds healed during the study timeframe. Reported as dichotomous yes/no.

Secondary Outcome Measures
NameTimeMethod
Wound VolumeBaseline

Wound volume measured by camera which performs a 3D measurement and calculates the volume at baseline

Wound AreaBaseline

Wound measured by camera which performs a 3D measurement and calculates the area at baseline

Tissue Oxygenation (StO2) of the Dorsal FootBaseline

Tissue oxygenation measured by hyperspectral imaging camera at baseline

Trial Locations

Locations (1)

UT Southwestern Medical Center at Dallas

🇺🇸

Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath